Buprenorphine dosing regime for inpatient heroin withdrawal: A symptom-triggered dose titration study

Drug and Alcohol Dependence

Volumn 70, Issue 3, 2003, Pages 287-294

  Lintzeris, Nicholas ^a,c   Bammer, Gabriele ^a   Rushworth, Louise ^d   Jolley, Damien J ^d   Whelan, Greg ^b  

^a The Australian National University   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NONE

Author keywords

Buprenorphine; Detoxification; Heroin withdrawal; Inpatient titration regime

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; PSYCHOSOCIAL DISORDER; RASH; SINGLE BLIND PROCEDURE; SYMPTOM; TABLET; TITRIMETRY; VERTIGO; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 0038325703     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(03)00015-2     Document Type: Article

References (32)

1. Andrews L., Himmelsbach C. Relation of the intensity of the morphine abstinence syndrome to dosage. J. Exp. Pharmacol. Ther. 81:1944;288-293.
2. Cheskin L.J., Fudala P.J., Johnson R.E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend. 36:1994;11-21.
3. Darke S., Heather N., Hall W., Ward J., Wodak A. Estimating drug consumption in opioid users: reliability and validity of a 'recent use' episodes method. Br. J. Addict. 86:1991;1311-1316.
4. Eisen S., Dill D., Grob M. Reliability and validity of a brief patient report instrument for psychiatric outcome evaluation. Hosp. Community Psychiatry. 45:1994;242-247.
5. Handelsman L., Cochrane K.J., Aronson M.J., Ness R.A., Rubinstein K.J., Kanof P.D. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse. 13:1987;293-308.
6. Jasinski D.R., Fudala P.J., Johnson R.E. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin. Pharmacol. Ther. 45:1989;513-519.
7. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 40:1995;17-25.
8. Kosten T.R., Kleber H.D. Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci. 42:1988;635-641.
9. Kosten T.R., Rounsaville B.J., Kleber H.D. Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. Am. J. Drug Alcohol Abuse. 11:1985;1-10.
10. Kosten T.R., Schottenfeld R., Ziedonis D., Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181:1993;358-364.
11. Kroenke K., Spitzer R. Gender differences in the reporting of physical and somatoform symptoms. Psychosom. Med. 60:1998;150-155.
12. Kutz I., Reznik V. Rapid heroin detoxification using a single high dose of buprenorphine. J. Psychoactive Drugs. 33:2001;191-193.
13. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S. Jr., Kintaudi P., Wesson D.R., McNicholas L., Tusel D.J., Malkerneker U., Renner J.A. Jr., Santos E., Casadonte P., Fye C., Stine S., Wang R.I., Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 93:1998;475-486.
14. Lintzeris, N., Clark, N., Muhleisen, P., Ritter, A., Ali, R., Bell, J., Gowing, L., Monheit, B., Quigley, A.J., Mattick, R., White, J., Whicker, S., 2001. National Clinical Guidelines on the Use of Buprenorphine in the Management of Heroin Dependence, National Drug Strategy, Commonwealth of Australia, Canberra.
15. Liu Z.M., Cai Z.J., Wang X.P., Ge Y., Li C.M. Rapid detoxification of heroin dependence by buprenorphine. Acta Pharmacol. Sin. 18:1997;112-114.
16. McQuay H.J., Bullingham R.E., Paterson G.M., Moore R.A. Clinical effects of buprenorphine during and after operation. Br. J. Anaesth. 52:1980;1013-1019.
17. Nigam A.K., Ray R., Tripathi M. Buprenorphine in opiate withdrawal: a comparison with clonidine. J. Subst. Abuse Treat. 10:1993;391-394.
18. Parran T.V., Adelman C.L., et al. A buprenorphine stabilization and rapid-taper protocol for the detoxification of opioid-dependent patients. Am. J. Addict. 3:1994;306-313.
19. Phillips G.T., Gossop M., Bradley B. The influence of psychological factors on the opiate withdrawal syndrome. Br. J. Psychiatry. 149:1986;235-238.
20. Raistrick D., Bradshaw J., Tober G., Weiner J., Allison J., Healey C. Development of the leeds dependence questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 89:1994;563-572.
21. Resnick R.B., Galanter M., Pycha C., Cohen A., Grandison P., Flood N. Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol. Bull. 28:1992;109-113.
22. Saitz R., Mayo-Smith M., Roberts M., Redmond H., Bernard D., Calkins D. Individualised treatment for alcohol withdrawal: a randomised double blind controlled trial. J. Am. Med. Assoc. 272:1994;519-523.
23. Schneider U., Paetzold W., Eronat V., Huber T.J., Seifert J., Wiese B., Emrich H.M. Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study. Addict. Biol. 5:2000;65-69.
24. Schottenfeld R.S., Pakes J., Ziedonis D., Kosten T.R. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry. 34:1993;66-74.
25. Schottenfeld R.S., Pakes J., Kosten T.R. Prognostic factors in buprenorphine- versus methadone-maintained patients. J. Nerv. Ment. Dis. 186:1998;35-43.
26. Schuh K.J., Johanson C.E. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 56:1999;55-60.
27. Seow S.S., Quigley A.J., Ilett K.F., Dusci L.J., Swensen G., Harrison-Stewart A., Rappeport L. Buprenorphine: a new maintenance opiate? Med. J. Aust. 144:1986;407-411.
28. Smolka M., Schmidt L.G. The influence of heroin dose and route of administration on the severity of the opiate withdrawal syndrome. Addiction. 94:1999;1191-1198.
29. Strang J., Griffiths P., Powis B., Gossop M. Heroin chasers and heroin injectors: differences observed in a community sample in London, UK. Am. J. Addict. 8:1999;148-160.
30. Tabachnik B., Fidell L. Using Multivariate Statistics. 1983;Harper & Row, New York, NY.
31. Umbricht A., Montoya I.D., Hoover D.R., Demuth K.L., Chiang C.T., Preston K.L. Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend. 56:1999;181-190.
32. Vignau J. Preliminary assessment of a 10-day rapid detoxification programme using high dosage buprenorphine. Eur. Addict. Res. 4:1998;29-31.